Pseudoephedrine
| Evidence Level: L2 | Predicted Indications: 3 |
Table of Contents
- Pseudoephedrine
- Pseudoephedrine: From Registered Cold, Flu and Sinus Products to Nasal Cavity Disease
Pseudoephedrine: From Registered Cold, Flu and Sinus Products to Nasal Cavity Disease
One-Sentence Summary
Pseudoephedrine is an oral decongestant sold in South Africa mainly in cold, flu and sinus combination products. The TxGNN model predicts it may be effective for nasal cavity disease. There are 19 registered clinical trials and 6 publications linked to this prediction, but only a few involve pseudoephedrine directly, and nasal decongestion is already its marketed use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration records (product names indicate cold, flu and sinus symptom relief) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L2 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the record. Pseudoephedrine is a known indirect sympathomimetic with alpha-adrenergic activity. It constricts blood vessels in the nasal lining, which reduces swelling and congestion. Mechanistically this fits nasal cavity disease well.
This may not be true repurposing. Nasal decongestion is already the marketed use of pseudoephedrine, and the registration records contain no approved-indication text. The prediction may therefore simply match the existing label. Confirm this against the approved SAHPRA label before treating it as a new indication.
Systemic use is also limited by effects on blood pressure, heart rate and the central nervous system.
Clinical Trial Evidence
The pack lists 19 trials for this prediction. Most are surgical, device or non-drug studies with no pseudoephedrine signal (for example sinus surgery, balloon sinuplasty, probiotics and saline sprays), so they are not shown. The most relevant are:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00804687 | Phase 2 | Completed | 53 | Single-dose, placebo-controlled three-way crossover comparing JNJ-39220675 and pseudoephedrine with placebo in allergic rhinitis, using an environmental exposure chamber. Pseudoephedrine served as the active comparator. |
| NCT00562120 | Phase 2 | Completed | 21 | Placebo-controlled four-way crossover of an H3 antagonist for congestion after nasal allergen challenge in seasonal allergic rhinitis. Pseudoephedrine’s role is unconfirmed because the title is truncated. |
| NCT03620513 | Phase 4 | Completed | 160 | Double-blind randomised study of topical anaesthesia, decongestant or both before fibreoptic laryngoscopy. It tests decongestants in general, and pseudoephedrine is not confirmed as the agent. |
| NCT00517946 | N/A | Completed | 21 | MRI used to assess the effect of anti-allergy drug treatment on nasal and sinus mucosa after allergen challenge in seasonal allergic rhinitis. |
| NCT01886768 | N/A | Unknown | 212 | Double versus single pledget nasal anaesthesia for transnasal endoscopy, with decongestion as a secondary aim. |
Overall, the direct clinical evidence is small (Phase 2 crossover studies of 21 to 53 participants). No SANCTR or PACTR registrations were identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11345158 | 2001 | Clinical comparative study (design not verified) | Am J Rhinol | Compared oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine, measured by acoustic rhinometry of nasal cavity dimensions. |
| 22794679 | 2012 | Review | Allergy Asthma Proc | Overview of nonallergic rhinitis, covering the shared symptoms of congestion, rhinorrhoea and postnasal discharge. |
| 19769798 | 2009 | Preclinical (feline) | Am J Rhinol Allergy | Loratadine and montelukast in a feline nasal congestion model. D-pseudoephedrine was also tested, with and without desloratadine. |
| 24492651 | 2014 | Preclinical (animal) | J Pharmacol Exp Ther | Selective α2c-adrenergic agonists in animal models of nasal congestion. |
| 12962193 | 2003 | Preclinical (dog) | Am J Rhinol | Model of allergic nasal congestion in ragweed-sensitised dogs, using acoustic rhinometry. |
| 12387934 | 2002 | Preclinical (dog) | J Pharmacol Toxicol Methods | Pharmacological characterisation of a chronic dog model of nasal congestion for studying decongestant mechanisms. |
South Africa Market Information
Twenty registrations are on record. The five main ones are below. The records give no approved-indication text and no Essential Medicines List (EML) status.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 36/5.8/0207 | Sinutab 3-way | Tablet | Not stated in record |
| Reg. No. 37/5.8/0138 | Sinutab sinus pain non-drowsy | Tablet | Not stated in record |
| Reg. No. T/5.8/196 | Sudafed sinus pain (was Sudagesic) 500mg | Tablet | Not stated in record |
| Reg. No. 36/5.8/0206 | Benylin daytime flu (was Benylin for col…) | Tablet | Not stated in record |
| Reg. No. 40/5.8/0218 | Ibumax cold & flu | Tablet | Not stated in record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
From the mechanism, systemic use is limited by effects on blood pressure, heart rate and the central nervous system. No drug interactions were found in the queried database.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism is direct and well established, and Phase 2 crossover trials in allergic rhinitis involve pseudoephedrine, which supports L2 evidence. The signal is probably consistent with the existing label rather than a novel indication, and direct trial evidence is small.
The other two predictions are not supported and should stay on Hold:
- Acute laryngopharyngitis (score 99.73%, L5): only an indirect symptomatic rationale, and no trials or publications.
- Allergic urticaria (score 99.14%, L4): pseudoephedrine has no antihistamine or mast-cell activity, and the association likely comes from co-formulation with antihistamines.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (a blocking gap for safety screening)
- The approved indication text from the SAHPRA labels, to confirm whether this is label-consistent
- Mechanism of action data from DrugBank
- Confirmation of pseudoephedrine’s role in NCT00562120 and NCT03620513
- A blood pressure, heart rate and CNS safety plan for at-risk populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.